vs

Side-by-side financial comparison of AVISTA CORP (AVA) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

AVISTA CORP is the larger business by last-quarter revenue ($533.0M vs $487.7M, roughly 1.1× CLOVER HEALTH INVESTMENTS, CORP.). AVISTA CORP runs the higher net margin — 13.3% vs -10.1%, a 23.4% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 0.0%). CLOVER HEALTH INVESTMENTS, CORP. produced more free cash flow last quarter ($-69.0M vs $-116.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -6.5%).

Avista Corporation is an American energy company which generates and transmits electricity and distributes natural gas to residential, commercial, and industrial customers. Approximately 1,550 employees provide electricity, natural gas, and other energy services to 359,000 electric and 320,000 natural gas customers in three western states. The service territory covers 30,000 square miles (78,000 km2) in eastern Washington, northern Idaho, and parts of southern and eastern Oregon, with a popul...

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

AVA vs CLOV — Head-to-Head

Bigger by revenue
AVA
AVA
1.1× larger
AVA
$533.0M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+44.7% gap
CLOV
44.7%
0.0%
AVA
Higher net margin
AVA
AVA
23.4% more per $
AVA
13.3%
-10.1%
CLOV
More free cash flow
CLOV
CLOV
$47.0M more FCF
CLOV
$-69.0M
$-116.0M
AVA
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-6.5%
AVA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AVA
AVA
CLOV
CLOV
Revenue
$533.0M
$487.7M
Net Profit
$71.0M
$-49.3M
Gross Margin
Operating Margin
21.0%
-10.1%
Net Margin
13.3%
-10.1%
Revenue YoY
0.0%
44.7%
Net Profit YoY
5.7%
-123.2%
EPS (diluted)
$0.87

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVA
AVA
CLOV
CLOV
Q4 25
$533.0M
$487.7M
Q3 25
$403.0M
$496.6M
Q2 25
$411.0M
$477.6M
Q1 25
$617.0M
$462.3M
Q4 24
$532.8M
$337.0M
Q3 24
$393.7M
$331.0M
Q2 24
$402.1M
$356.3M
Q1 24
$609.4M
$346.9M
Net Profit
AVA
AVA
CLOV
CLOV
Q4 25
$71.0M
$-49.3M
Q3 25
$29.0M
$-24.4M
Q2 25
$14.0M
$-10.6M
Q1 25
$79.0M
$-1.3M
Q4 24
$67.2M
$-22.1M
Q3 24
$18.5M
$-9.2M
Q2 24
$22.9M
$7.4M
Q1 24
$71.5M
$-19.2M
Gross Margin
AVA
AVA
CLOV
CLOV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Q1 24
23.6%
Operating Margin
AVA
AVA
CLOV
CLOV
Q4 25
21.0%
-10.1%
Q3 25
14.9%
-4.9%
Q2 25
13.9%
-2.2%
Q1 25
20.3%
-0.3%
Q4 24
19.1%
-6.4%
Q3 24
12.4%
-2.7%
Q2 24
13.5%
2.0%
Q1 24
16.6%
-6.5%
Net Margin
AVA
AVA
CLOV
CLOV
Q4 25
13.3%
-10.1%
Q3 25
7.2%
-4.9%
Q2 25
3.4%
-2.2%
Q1 25
12.8%
-0.3%
Q4 24
12.6%
-6.6%
Q3 24
4.7%
-2.8%
Q2 24
5.7%
2.1%
Q1 24
11.7%
-5.5%
EPS (diluted)
AVA
AVA
CLOV
CLOV
Q4 25
$0.87
Q3 25
$0.36
Q2 25
$0.17
Q1 25
$0.98
Q4 24
$0.86
Q3 24
$0.23
Q2 24
$0.29
Q1 24
$0.91

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVA
AVA
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$19.0M
$78.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.7B
$308.7M
Total Assets
$8.4B
$541.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVA
AVA
CLOV
CLOV
Q4 25
$19.0M
$78.3M
Q3 25
$44.0M
Q2 25
$9.0M
Q1 25
$17.0M
Q4 24
$30.0M
$194.5M
Q3 24
$9.1M
$288.0M
Q2 24
$14.6M
$254.8M
Q1 24
$12.3M
$208.3M
Stockholders' Equity
AVA
AVA
CLOV
CLOV
Q4 25
$2.7B
$308.7M
Q3 25
$2.6B
$340.9M
Q2 25
$2.6B
$344.2M
Q1 25
$2.6B
$336.1M
Q4 24
$2.6B
$341.1M
Q3 24
$2.5B
$342.2M
Q2 24
$2.5B
$324.9M
Q1 24
$2.5B
$292.5M
Total Assets
AVA
AVA
CLOV
CLOV
Q4 25
$8.4B
$541.0M
Q3 25
$8.2B
$559.7M
Q2 25
$8.1B
$575.0M
Q1 25
$8.0B
$583.7M
Q4 24
$7.9B
$580.7M
Q3 24
$7.8B
$653.0M
Q2 24
$7.7B
$674.2M
Q1 24
$7.6B
$671.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVA
AVA
CLOV
CLOV
Operating Cash FlowLast quarter
$75.0M
$-66.9M
Free Cash FlowOCF − Capex
$-116.0M
$-69.0M
FCF MarginFCF / Revenue
-21.8%
-14.1%
Capex IntensityCapex / Revenue
35.8%
0.4%
Cash ConversionOCF / Net Profit
1.06×
TTM Free Cash FlowTrailing 4 quarters
$-101.0M
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVA
AVA
CLOV
CLOV
Q4 25
$75.0M
$-66.9M
Q3 25
$170.0M
$12.1M
Q2 25
$40.0M
$5.4M
Q1 25
$184.0M
$-16.3M
Q4 24
$89.8M
$34.8M
Q3 24
$127.2M
$50.0M
Q2 24
$126.8M
$44.8M
Q1 24
$190.1M
$25.9M
Free Cash Flow
AVA
AVA
CLOV
CLOV
Q4 25
$-116.0M
$-69.0M
Q3 25
$37.0M
$11.4M
Q2 25
$-103.0M
$4.8M
Q1 25
$81.0M
$-16.5M
Q4 24
$-37.8M
$33.3M
Q3 24
$-27.0M
$49.6M
Q2 24
$-5.7M
$44.4M
Q1 24
$71.4M
$25.5M
FCF Margin
AVA
AVA
CLOV
CLOV
Q4 25
-21.8%
-14.1%
Q3 25
9.2%
2.3%
Q2 25
-25.1%
1.0%
Q1 25
13.1%
-3.6%
Q4 24
-7.1%
9.9%
Q3 24
-6.9%
15.0%
Q2 24
-1.4%
12.5%
Q1 24
11.7%
7.3%
Capex Intensity
AVA
AVA
CLOV
CLOV
Q4 25
35.8%
0.4%
Q3 25
33.0%
0.1%
Q2 25
34.8%
0.1%
Q1 25
16.7%
0.0%
Q4 24
23.9%
0.5%
Q3 24
39.2%
0.1%
Q2 24
33.0%
0.1%
Q1 24
19.5%
0.1%
Cash Conversion
AVA
AVA
CLOV
CLOV
Q4 25
1.06×
Q3 25
5.86×
Q2 25
2.86×
Q1 25
2.33×
Q4 24
1.34×
Q3 24
6.88×
Q2 24
5.55×
6.04×
Q1 24
2.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons